Drug Profile
Idursulfase - Takeda
Alternative Names: DRX 006A; Elaprase; GC-1111 - Sanofi Genzyme; HGT-2310; I2S; Iduronate-2-sulfatase-gene-therapy; Idursulfase-beta; idursulfase-IT; Recombinant-iduronate-2-sulfatase - Takeda; SHP-609; TAK 609Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Sanofi; Takeda
- Class Iduronate sulfatases; Recombinant proteins
- Mechanism of Action Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mucopolysaccharidosis II
Most Recent Events
- 05 Mar 2024 Phase-II/III clinical trials in Mucopolysaccharidosis II (In children, In adolescents, In adults) in Canada (Intrathecal) (NCT06031259)
- 11 Sep 2023 Takeda plans a phase II/III open-label extension trial for Mucopolysaccharidosis II (In children, In adolescents) in Canada and France (Intrathecal, Injection, once monthly) (NCT06031259)
- 03 Apr 2023 Takeda initiates a post-trial, expanded access program for Idursulfase in Mucopolysaccharidosis II (In children, In adolescent) (IV) (NCT05795361)